Allison Swartz - Progyny General Secretary
| PGNY Stock | USD 15.57 0.09 0.58% |
Executive
Allison Swartz is General Secretary of Progyny
| Age | 34 |
| Address | 1359 Broadway, New York, NY, United States, 10018 |
| Phone | 212 888 3124 |
| Web | https://www.progyny.com |
Allison Swartz Latest Insider Activity
Tracking and analyzing the buying and selling activities of Allison Swartz against Progyny stock is an integral part of due diligence when investing in Progyny. Allison Swartz insider activity provides valuable insight into whether Progyny is net buyers or sellers over its current business cycle. Note, Progyny insiders must abide by specific rules, including filing SEC forms every time they buy or sell Progyny'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Allison Swartz over three months ago Disposition of 1352 shares by Allison Swartz of Progyny at 21.59 subject to Rule 16b-3 |
Progyny Management Efficiency
The company has return on total asset (ROA) of 0.059 % which means that it generated a profit of $0.059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1205 %, meaning that it created $0.1205 on every $100 dollars invested by stockholders. Progyny's management efficiency ratios could be used to measure how well Progyny manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.09 in 2024. Return On Capital Employed is likely to rise to 0.11 in 2024. At this time, Progyny's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 440.7 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 69.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joseph Cpa | Teladoc | 56 | |
| Jack Callahan | Phreesia | N/A | |
| Ryan Barry | Health Catalyst | N/A | |
| Craig Hazenfield | Definitive Healthcare Corp | N/A | |
| Jonathan Weinberg | Evolent Health | 53 | |
| Jenny Harding | Privia Health Group | N/A | |
| Florian Baumgartner | 10X Genomics | N/A | |
| CPA CFA | Teladoc | N/A | |
| Brian Wagener | Veeva Systems Class | 42 | |
| Mark Mannion | Evolent Health | N/A | |
| Jonathan JD | Evolent Health | 56 | |
| Michael JD | HealthStream | 48 | |
| Eric Beyer | Privia Health Group | N/A | |
| Michele OConnor | Veeva Systems Class | 47 | |
| Tarah Bryan | Health Catalyst | N/A | |
| Ram Sharma | Definitive Healthcare Corp | N/A | |
| Andy Monnich | National Research Corp | 48 | |
| Cassie Corneau | 10X Genomics | N/A | |
| Scott Fenstermacher | HealthStream | 55 | |
| Matthew Robinson | Veeva Systems Class | 50 | |
| Adam Vandervoort | Teladoc | 49 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.059 |
Progyny Leadership Team
Elected by the shareholders, the Progyny's board of directors comprises two types of representatives: Progyny inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Progyny. The board's role is to monitor Progyny's management team and ensure that shareholders' interests are well served. Progyny's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Progyny's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Stadlbauer, Ex Partnerships | ||
| Katie Higgins, Chief Officer | ||
| Risa Fisher, Chief Officer | ||
| Cassandra Pratt, Senior People | ||
| Peter Anevski, CEO Director | ||
| Steven Leist, Chief Officer | ||
| Michael Sturmer, President | ||
| Mark CPA, Chief Officer | ||
| Allison Swartz, General Secretary | ||
| James Hart, Vice Relations | ||
| Arielle Bogorad, Senior Strategy | ||
| Mark Livingston, Chief Officer | ||
| David JD, Executive Chairman | ||
| Peter CPA, CEO Director | ||
| Janet MD, Member Officer | ||
| David Schlanger, Executive Chairman |
Progyny Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Progyny a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.059 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 1.1 B | ||||
| Shares Outstanding | 85.15 M | ||||
| Shares Owned By Insiders | 6.90 % | ||||
| Shares Owned By Institutions | 93.10 % | ||||
| Number Of Shares Shorted | 11.42 M | ||||
| Price To Earning | 37.91 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Progyny Stock Analysis
When running Progyny's price analysis, check to measure Progyny's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Progyny is operating at the current time. Most of Progyny's value examination focuses on studying past and present price action to predict the probability of Progyny's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Progyny's price. Additionally, you may evaluate how the addition of Progyny to your portfolios can decrease your overall portfolio volatility.